Latest Media Releases

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Phylogica, Investor Presentation: Harnessing Biodiversity for Peptide Therapeutics (ASX:PYC)

Corporate Overview - Operations in Perth, Australia. - Phylomer peptide libraries derived from most structurally diverse genomes. - &#...read more

Phylogica Ltd, Half Yearly Report and Accounts (ASX:PYC)

Appendix 4D Half-Year Statement Period ending 31 December 2013 Results for announcement to the market To view Report please download PDF below:

Phylogica, Director Appointment - Dr Bernard Hockings (ASX:PYC)

PERTH, AUSTRALIA: 24 January 2014 – Leading peptide drug discovery company Phylogica Ltd (ASX:PYC, XETRA:PH7) is pleased to announce the appointment of Dr Bernard Hockings as a director. ...read more

Phylogica, Entitlement Issue Result and Shortfall (ASX:PYC)

Phylogica Limited advises that the Entitlement Offer and Shortfall Offer has concluded with acceptances for 87% of the issue. For further information please download PDF b...read more

Phylogica Ltd, Offer Document (ASX:PYC)

For a pro rata non-renounceable entitlement issue to Eligible Shareholders on the basis of two (2) New Shares for every three (3) Shares held by Shareholders on the Record Date at an issue price of...read more

Phylogica, Presentation November 2013: Harnessing Biodiversity for Peptide Therapeutics (ASX:PYC)

Recent Highlights - Expanded Janssen collaboration on peptide-drug conjugates to include downstream bilogical validation of optimal hits. - Constructed 2nd generation libraries ...read more

Phylogica, Rights Issue Update (ASX:PYC)

PERTH, AUSTRALIA: 25 November 2013 – Leading peptide drug discovery company Phylogica Ltd (ASX:PYC, XETRA:PH7) provides the following update in relation to the Recapitalisation announcements ...read more

Phylogica, Recapitalisation Update (ASX:PYC)

PERTH, AUSTRALIA: 18 November 2013 – Leading peptide drug discovery company Phylogica Ltd (ASX:PYC, XETRA:PH7) provides the following update in relation to the Recapitalisation announcement m...read more

Phylogica, Basis for Recapitalisation of the Company Agreed (ASX:PYC)

- Fully Underwritten Rights Issue to Raise $6 Million - Converting Note Conversion Details Agreed PERTH, AUSTRALIA: 11 November 2013 – Leading peptide drug discovery company...read more

Phylogica, Investor Presentation: Harnessing Biodiversity for Peptide Therapeutics (ASX:PYC)

Summary - Assembled and validated a world-class peptide drug discovery platform. - Patent protection on worlds largest source of naturally structured peptides and related screen...read more

Phylogica, US Patent for Synthetic Phylomer Libraries Allowed (ASX:PYC)

- US Patent allowed for rationally designed synthetic Phylomer libraries; - Broad applications of synthetic Phylomer libraries in therapeutics and diagnostics; - Patent allowa...read more

Phylogica, Shareholder Newsletter: Breakthrough Peptide Therapeutics (ASX:PYC)

In this edition: - Phylogica launches a new disruptive technology: the Endosome Escape Trap - Janssen expansion driven by delivery on goals of CPP discovery project - ...read more

Phylogica Ltd, Appendix 4E - Preliminary Final Report - Year Ended 30 June 2013 (ASX:PYC)

Business Strategy Phylogica is a specialist drug discovery Company offering peptide discovery services to the pharmaceutical industry in exchange for upfront licence fees, milestone payments an...read more

Phylogica, Collaboration with Cubist to Evaluate Antimicrobial Phylomers (ASX:PYC)

PERTH, AUSTRALIA: July 25th 2013. Phylogica Ltd (ASX:PYC, XETRA: PH7) a leading Australian peptide drug discovery company, announces a collaboration with Cubist Pharmaceuticals, Inc. (NASDAQ: CBST)...read more

Phylogica, Richard Hopkins Appointed CEO (ASX:PYC)

PERTH, AUSTRALIA: 19 July 2013: Leading Australian peptide drug discovery company Phylogica Limited (ASX:PYC, XETRA:PH7) has appointed Dr Richard Hopkins as the company’s new Chief Executive ...read more

Viewing: 61 - 75 of 116 Previous | Next